News & Updates

Show Multimedia Only

Product Highlight - Comirnaty

12 Jun 2024

Raxtozinameran - Dispersion for injection

Product Highlight - Comirnaty

12 Jun 2024

Pooled data support linaclotide for IBS-C irrespective of age

12 Jun 2024 by

Treatment with linaclotide significantly improved abdominal symptoms and the frequency of complete spontaneous bowel movements (CSBMs) among adult and elderly patients with irritable bowel syndrome with constipation (IBS-C), according to the pooled analysis of three phase III trials presented at DDW 2024.

Pooled data support linaclotide for IBS-C irrespective of age

12 Jun 2024

Dual ACE inhibitor plus ARB therapy worsens kidney status in CKD

11 Jun 2024 by

Use of dual therapy with ACE inhibitors and ARBs tends to elevate the risk of renal outcomes in people with or without chronic kidney disease (CKD), reports a study presented at ERA 2024.

Dual ACE inhibitor plus ARB therapy worsens kidney status in CKD

11 Jun 2024

Oral tacrolimus benefits haemodialysis patients with uraemic pruritus

11 Jun 2024 by

A study from Iran presented at ERA 2024 demonstrated the potential of oral tacrolimus to deliver an antipruritic effect in haemodialysis patients with uraemic pruritus.

Oral tacrolimus benefits haemodialysis patients with uraemic pruritus

11 Jun 2024

Tirzepatide resolves MASH without worsening fibrosis

11 Jun 2024 by

Treatment with tirzepatide for 52 weeks resulted in MASH* resolution, with no worsening of fibrosis in patients with MASH and fibrosis in the phase II SYNERGY-NASH trial.

Tirzepatide resolves MASH without worsening fibrosis

11 Jun 2024

Iptacopan safe, effective in patients with C3G

10 Jun 2024 by

Use of iptacopan along with supportive care results in significant reductions in proteinuria at 6 months in patients with C3 glomerulopathy (C3G), a rare and severe form of proliferative glomerulonephritis brought about by the dysregulation of alternative complement pathway (AP), as shown in the APPEAR-C3G study. It is also well tolerated and has a favourable safety profile.

Iptacopan safe, effective in patients with C3G

10 Jun 2024

Reduced-dose DOACs tied to lower stroke incidence vs warfarin

10 Jun 2024

Patients with atrial fibrillation receiving a reduced dose of direct acting oral anticoagulants (DOAC), particularly rivaroxaban and dabigatran, show a similar incidence of ischaemic stroke and systemic embolism to those receiving warfarin, a study has shown.

Reduced-dose DOACs tied to lower stroke incidence vs warfarin

10 Jun 2024

Original New Drug Application Approvals by US FDA (16-31 May 2024)

10 Jun 2024

New drug applications approved by US FDA as of 16-31 May 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 May 2024)

10 Jun 2024

Olezarsen benefits hypertriglyceridemia patients at high cardiovascular risk

10 Jun 2024

Treatment with olezarsen in patients with hypertriglyceridemia and elevated cardiovascular risk results in substantial reductions in triglyceride, apolipoprotein B, and non–high-density lipoprotein cholesterol levels, while having no major safety signals, according to data from the phase IIb Bridge–TIMI 73a study.

Olezarsen benefits hypertriglyceridemia patients at high cardiovascular risk

10 Jun 2024

Benefits of investigational IgA nephropathy drug persist for 72 weeks

09 Jun 2024 by

Patients with IgA nephropathy (IgAN) who have been treated with atacicept continue to show improvement in disease status through 72 weeks, with consistent reductions in the key indicators of IgAN and the kidney function remaining stable, according to the open-label extension phase of the phase IIb ORIGIN study.

Benefits of investigational IgA nephropathy drug persist for 72 weeks

09 Jun 2024

News & Updates

Filter by Specialty:

Specialty:

Product Highlight - Comirnaty

Product Highlight - Comirnaty

Pooled data support linaclotide for IBS-C irrespective of age

Pooled data support linaclotide for IBS-C irrespective of age

Dual ACE inhibitor plus ARB therapy worsens kidney status in CKD

Dual ACE inhibitor plus ARB therapy worsens kidney status in CKD

Oral tacrolimus benefits haemodialysis patients with uraemic pruritus

Oral tacrolimus benefits haemodialysis patients with uraemic pruritus

Tirzepatide resolves MASH without worsening fibrosis

Tirzepatide resolves MASH without worsening fibrosis

Iptacopan safe, effective in patients with C3G

Iptacopan safe, effective in patients with C3G

Reduced-dose DOACs tied to lower stroke incidence vs warfarin

Reduced-dose DOACs tied to lower stroke incidence vs warfarin

Original New Drug Application Approvals by US FDA (16-31 May 2024)

Original New Drug Application Approvals by US FDA (16-31 May 2024)

Olezarsen benefits hypertriglyceridemia patients at high cardiovascular risk

Olezarsen benefits hypertriglyceridemia patients at high cardiovascular risk

Benefits of investigational IgA nephropathy drug persist for 72 weeks

Benefits of investigational IgA nephropathy drug persist for 72 weeks